FOLFIRI方案治疗常规化疗失败晚期大肠癌的疗效分析

Clinical study of FOLFIRI regimen for patients with resistant in the treatment of advanced colorectal cancer

目的:探讨FOLFIRI方案治疗常规化疗失败晚期大肠癌患者的临床疗效和不良反应。方法:常规化疗失败的晚期大肠癌患者25例,开普拓(Irinotecan,CPT-11)180mg/m2,静脉滴注,d1;FA200mg/m2,静脉滴注,d1-2;5-FU400mg/m2静脉推注,然后5-FU600mg/m2持续静脉滴注22h,d1-2,每2周重复,2次为1个周期,共行1-6个周期,中位周期1.5个。结果:25例患者,PR9例,SD10例,PD6例,总缓解率36.0%,中位缓解时间3.0-13.5个月。主要不良反应为迟发性腹泻和中性粒细胞减少,Ⅲ-Ⅳ度发生率分别为25.6%(11/43)和41.9%(18/43)。结论:FOLFIRI方案是治疗常规化疗失败晚期大肠癌的有效化疗方案,缓解率较高,迟发性腹泻和中性粒细胞减少为其主要不良反应。

Objective：To observe the efficacy and toxicity of FOLFIRI regimen for the patients with resistant advanced colorectal cancer. Methods：All patients received 1 to 6 cycle FOLFIRI cycles （ irinotecan 180mg/m^2, d1, leucovorin 200mg.（m2, d1 , followed by bolus 400mg/m^2 5 - FU and by a 22 - hour 600mg/m^2 5 - FU infusion, every 2 weeks repeated,6 weeks a cycle）. Results：All the 25 patients were treated with FOLFIRI regimen. The response rate was 36.0% （9/25） ,including 9 partial responses （PR） ,but no complete responses （CR）. Main toxicityies were delayed diarrhea and neutropenia. The incidence of grade Ⅲ - Ⅳ neutropenia was 41.9% （ 18/43 ） and the grade Ⅲ - Ⅳ delayed diarrhea was 25.6% （11/43）. Other toxicities were mild. Conclusion： FOLFIRI regimen is effective for the patients with resistant advanced colorectal cancer. Main toxicity is delayed diarrhea and neutropenia. The response rate is high.